Aurobindo Pharma's CuraTeQ Biologics completes Phase 1 study of bone drug
Aurobindo Pharma's CuraTeQ Biologics reported successful trial results for BP16, a bone treatment drug. BP16 showed bioequivalence to Prolia in trials with 204 volunteers.
What's Your Reaction?



